readthroughSign in
Nov 16, 2026Publication

Helus Pharma to present Phase 3 APPROACH topline results for HLP003 on Nov 16

The company announced a webcast to share topline results from its Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder.

Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) said on November 15, 2026 that it would hold a webcast the following morning at 8:00 a.m. EDT to share topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder.1 The webcast is scheduled for Monday, November 16, 2026, and an archived version will be posted afterward on the company's website under its Events & Presentations page.

Helus Pharma describes itself as a clinical-stage company focused on mental health treatments built around what it calls novel serotonergic agonists, or NSAs. According to the company, these are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.1

HLP003, the drug candidate at the center of the APPROACH study, is being developed in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.1 The company is also advancing a second candidate, HLP004, which is in Phase 2 development for generalized anxiety disorder.1 Beyond these two programs, Helus Pharma said it maintains an extensive research portfolio of investigational NSAs.1

The company operates across Canada, the United States, the United Kingdom, and Ireland.1

Helus Pharma cautioned that it makes no medical, treatment or health benefit claims about its proposed products, and that the FDA, Health Canada, and other regulators have not evaluated claims regarding NSAs, HLP003, HLP004 or the company's other programs.1 The company added that there is no assurance these programs can diagnose, treat, cure or prevent any disease, and that further scientific research and clinical trials are needed.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.